Skip to content
Screener

Monopar Therapeutics MNPR Q2 2025 earnings

Reported August 12, 2025 · Before market open

Revenue-
EPS-$0.35Beat by $0.12
EPS estimate-$0.47

Next report

Nov 6, 2026 (in 3 months)
EPS estimate-$0.77

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$3.2M-80.8%
Net income-$2.5M-43.0%

Balance sheet

See full
Cash & equivalents$39.5M+545%
Total debt$113.7K—
Total equity$52.2M+757%
Total assets$53.9M+650%

Cash flow

See full
Operating cash flow-$1.1M+35.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$203.64M+1,495%
Enterprise value$164.25M—

Returns & leverage

See full
Return on equity-59.4%-17.6pp
Debt / equity0×—
Current ratio33.9×—

FAQ

When did Monopar Therapeutics report Q2 2025 earnings?
Monopar Therapeutics (MNPR) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Monopar Therapeutics's Q2 2025 revenue and EPS?
Monopar Therapeutics reported revenue of - and eps of $-0.35 for Q2 2025.
Did Monopar Therapeutics beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.47 by $0.12.
How did Monopar Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 30.0% from $-0.50.
Where can I find Monopar Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001437749-25-026043) and the 10-Q periodic report (0001437749-25-026042) directly on SEC EDGAR. The filing index links above go to sec.gov.